Transcode Therapeutics Inc
RNAZ
查看详细走势图
7.380USD
-0.150-1.99%
收盘 12/24, 13:00（美东）报价延迟15分钟
6.15M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-1.99%
5天
-12.77%
1月
-18.45%
6月
-5.26%
今年开始到现在
-92.18%
1年
-92.51%
查看详细走势图
TradingKey Transcode Therapeutics Inc股票评分
单位: USD 更新时间: 2025-10-27操作建议
当前估值合理，机构持股占比非常高，近一月多位分析师给出公司评级为。最高目标价max_target_price。目前股价在压力位和支撑位之间，可以做区间波段操作。
Transcode Therapeutics Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
0
位分析师
--
评级
10.000
目标均价
+2266.86%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Transcode Therapeutics Inc亮点
亮点风险
TransCode Therapeutics, Inc. is a clinical-stage oncology company focused on treating metastatic disease. It is defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. Its lead candidate, TTX-MC138, targets metastatic tumors overexpressing microRNA-10b, a biomarker of metastasis. The Company is also developing a portfolio of RNA therapeutic candidates to overcome delivery challenges and unlock access to novel genetic targets. Its preclinical programs include TTX-siPDL1 (siRNA modulator of PD-L1), TTX-RIGA (RNA agonist of RIG-I for innate immunity activation), and TTX-siMYC (siRNA inhibitor of c-MYC). Additionally, R&D efforts are exploring the combination of TTX-MC138 and seviprotimut-L technologies to enhance therapeutic impact.
Transcode Therapeutics Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Transcode Therapeutics Inc简介
TransCode Therapeutics, Inc. is a clinical-stage oncology company focused on treating metastatic disease. It is defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. Its lead candidate, TTX-MC138, targets metastatic tumors overexpressing microRNA-10b, a biomarker of metastasis. The Company is also developing a portfolio of RNA therapeutic candidates to overcome delivery challenges and unlock access to novel genetic targets. Its preclinical programs include TTX-siPDL1 (siRNA modulator of PD-L1), TTX-RIGA (RNA agonist of RIG-I for innate immunity activation), and TTX-siMYC (siRNA inhibitor of c-MYC). Additionally, R&D efforts are exploring the combination of TTX-MC138 and seviprotimut-L technologies to enhance therapeutic impact.
公司代码RNAZ
公司Transcode Therapeutics Inc
CEOCalais (Philippe P)
网址https://www.transcodetherapeutics.com/
常见问题
Transcode Therapeutics Inc(RNAZ)的当前股价是多少？
Transcode Therapeutics Inc(RNAZ)的当前股价是 7.380。
Transcode Therapeutics Inc的股票代码是什么？
Transcode Therapeutics Inc的股票代码是RNAZ。
Transcode Therapeutics Inc股票的52周最高点是多少？
Transcode Therapeutics Inc股票的52周最高点是468.440。
Transcode Therapeutics Inc股票的52周最低点是多少？
Transcode Therapeutics Inc股票的52周最低点是6.148。
Transcode Therapeutics Inc的市值是多少？
Transcode Therapeutics Inc的市值是6.15M。
Transcode Therapeutics Inc的净利润是多少？
Transcode Therapeutics Inc的净利润为-16.82M。
现在Transcode Therapeutics Inc(RNAZ)的股票是买入、持有还是卖出？
根据分析师评级，Transcode Therapeutics Inc(RNAZ)的总体评级为--，目标价格为10.000。
Transcode Therapeutics Inc(RNAZ)股票的每股收益（EPS TTM）是多少
Transcode Therapeutics Inc(RNAZ)股票的每股收益（EPS TTM）是-238.843。
相关品种
